It is very uncertain whether parenteral iron changes mortality compared with oral iron (very low certainty).
It is very uncertain whether parenteral iron changes proportion requiring blood transfusion compared with oral iron (very low certainty).
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).
It is very uncertain whether parenteral iron changes serious adverse events compared with inactive control (very low certainty).
It is very uncertain whether parenteral iron changes mortality compared with inactive control (very low certainty).
It is very uncertain whether parenteral iron changes proportion requiring blood transfusion compared with inactive control (very low certainty).
Patient‐centred outcomes for oral showed no clear difference in death (all causes) compared with IV iron (low certainty).
It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
The intervention probably leads to lower low Hb deferral ‐ at first donation visit after commencement of… (moderate certainty).
The intervention probably leads to lower low Hb deferral ‐ after multiple donation visits (moderate certainty).